Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 225

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study

Smith, V, Van Praet, J T, Vandooren, B, Van der Cruyssen, B, Naeyaert, J-M, Decuman, S, Elewaut, D, De Keyser, F·2010·Annals of the Rheumatic Diseases

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/ard.2008.095463

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 12

  1. Sakkas, 2006, Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis., Nat Clin Pract Rheumatol, 2, 679, 10.1038/ncprheum0346 · DOI · Paper page
  2. Walker, 2007, Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database., Ann Rheum Dis, 66, 754, 10.1136/ard.2006.062901 · DOI · Paper page
  3. Lafyatis, 2006, Rituximab treatment for patients with diffuse cutaneous systemic sclerosis – a phase I study., Arthritis Rheum, 54, S523
  4. Lombardi, 2008, Rituximab for the long term treatment of severe cutaneous involvement in systemic sclerosis., Arthritis Rheum, 58, S822
  5. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, 1980, Preliminary criteria for the classification of systemic sclerosis (scleroderma)., Arthritis Rheum, 23, 581, 10.1002/art.1780230510 · DOI · Paper page
  6. Valentini, 2001, European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes., Ann Rheum Dis, 60, 592, 10.1136/ard.60.6.592 · doi:10.1136/ard.60.6.592
  7. Rannou, 2007, Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), systemic sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey., Arthritis Rheum, 57, 94, 10.1002/art.22468 · DOI · Paper page
  8. Teng, 2007, Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment., Arthritis Rheum, 56, 3909, 10.1002/art.22967 · DOI · Paper page
  9. Steen, 1998, Case–control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis., Arthritis Rheum, 41, 1613, 10.1002/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O · doi:10.1002/1529-0131(199809)41:9<1613::aid-art11>3.0.co;2-o
  10. DeMarco, 2002, Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose d-penicillamine in early diffuse systemic sclerosis trial., Arthritis Rheum, 46, 2983, 10.1002/art.10589 · DOI · Paper page
  11. Gazi, 2007, Outcome measurements in scleroderma: results from a delphi exercise., J Rheumatol, 34, 501
  12. Denton, 2007, Recombinant human anti-transforming growth factor beta 1 antibody therapy in systemic sclerosis – a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192., Arthritis Rheum, 56, 323, 10.1002/art.22289 · DOI

Cited by

See all 225

Metadata

Authors
Smith, V, Van Praet, J. T., Vandooren, B., Van der Cruyssen, B., Naeyaert, J.-M., Decuman, S., Elewaut, D., & De Keyser, F.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2010-01
Volume
69
Issue
1
Pages
193-197
ISSN
0003-4967 (ISSN-L)
OpenAlex
W2156105259
Cited by
225
References
2
FWCI
9.69
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. https://app.cochat.ai/papers/10.1136/ard.2008.095463
The paper
Smith, V, Van Praet, J. T., Vandooren, B., Van der Cruyssen, B., Naeyaert, J.-M., Decuman, S., Elewaut, D., & De Keyser, F. (2010). Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Annals of the Rheumatic Diseases. https://doi.org/10.1136/ard.2008.095463

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.